PSMA Targeted Activated Dendritic Cells therapy (Frontiergate Biopharm)

PSMA靶向激活树突状细胞疗法（珈钰生物医药）

Report date: 2026/04/17 20:02:02

Base Information

Drug NamePSMA Targeted Activated Dendritic Cells therapy (Frontiergate Biopharm)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Chimeric antigen receptor dendritic cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionDendritic cells modulatorsAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesFrontiergate Biopharm (Hainan) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesFrontiergate Biopharm (Hainan) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A